CGEN

Compugen Ltd.

2.60 USD
+0.03 (+1.17%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Compugen Ltd. stock is up 1.17% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 23 February’s closed higher than January.

About Compugen Ltd.

Compugen Ltd. researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors. COM902, a therapeutic antibody targeting TIGIT, and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, are in clinical study in patients with advanced or metastatic non-small cell lung cancer.